Printed from Voxsanity (voxsanity.com.au) — NCT06383507 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 1 Ovarian Cancer Trial, Not Yet Recruiting
NCT06383507
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are able to understand and sign a written consent form.
- People aged 18 years or older, of any gender.
- People who have been confirmed by tissue testing to have advanced or metastatic solid tumours that have not responded to at least two previous treatment lines, or who have been newly diagnosed with advanced or metastatic solid tumours for which no standard first-line treatment is recommended by clinical guidelines.
- People whose tumour tissue (tested by biopsy or cell sample) shows a positive result for a protein called CD70 at a level confirmed by laboratory analysis (confirm with trial site).
- People who have at least one measurable tumour area that can be tracked on scans, as assessed using standard measurement criteria (RECIST v1.1).
- People whose expected survival is more than 12 weeks.
- People with a general health performance score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physical activity.
- People whose blood cell counts fall within the required ranges: neutrophils at least 1.5×10⁹/L, platelets at least 90×10⁹/L, haemoglobin at least 90 g/dL, and white blood cells at least 3.0×10⁹/L.
- People whose kidney function is within an acceptable range, with serum creatinine no more than 1.5 times the upper limit of normal.
- People whose liver function is within acceptable ranges for bilirubin and liver enzymes (ALT and AST), with slightly different thresholds depending on whether the cancer has spread to the liver (confirm with trial site).
- People whose blood clotting function is within acceptable ranges (INR and APTT both no more than 1.5 times the upper limit of normal).
- People who agree to use reliable contraception (not including rhythm-based methods) from the time of signing the consent form until at least 6 months after receiving the treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously received any treatment targeting the CD70 protein.
- People who have received anti-cancer treatments such as chemotherapy or targeted therapy within the 2 weeks before treatment, or within at least 5 half-lives of the drug — whichever period is longer.
- People who have been taking systemic steroid medications at a dose greater than 10 mg per day of prednisone (or an equivalent dose of another steroid) within the 2 weeks before treatment.
- People who are pregnant, currently breastfeeding, or lactating.
- People who test positive for certain infections, including active hepatitis B or C (with detectable virus levels in the blood), HIV, syphilis, or cytomegalovirus (CMV) (confirm with trial site for exact testing thresholds).
- People with certain serious heart conditions, including severe heart failure (NYHA stage III or IV), a heart attack or bypass surgery within the past 6 months, significant irregular heart rhythms, or a heart pumping function below 50% on an echocardiogram.
- People with active or symptomatic cancer spread to the brain or the lining of the brain at the time of screening; people with previously treated brain metastases must have had stable scans for at least 4 weeks after completing that treatment before being considered.
- People who have previously had an organ transplant from another person, or a stem cell transplant from a donor.
- People who have received any vaccination within 14 days before enrolling in the study.
- People who have received a live attenuated vaccine within 4 weeks before screening.
- People who have had a different type of cancer within the past 3 years, unless that cancer was treated with curative intent and there has been no known active disease for 3 or more years.
- People who have a serious or uncontrolled illness affecting the whole body, such as uncontrolled high blood pressure, uncontrolled high blood sugar, significant liver or kidney problems, metabolic conditions, or central nervous system diseases.
- People whom the trial investigators consider unsuitable for participation for other reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 691655
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Zhejiang University
Registry
ClinicalTrials.gov
Start date
22 April 2024
Est. completion
21 April 2027
Primary endpoints
Incidence of Adverse events after CD70 UCAR-T cells infusion (Safety and Tolerability)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.